Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 91

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 91
---
 you can identify forward-looking statements by terminology such as
“aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our clinical trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | our ability to accurately identify demand for our Gelrin hydrogel platform or any future product candidates; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates; |

| ● | our ability to obtain FDA approval for our GelrinC product and obtain and maintain regulatory approval of our future product candidates; |

| ● | our ability to obtain market acceptance of our Gelrin hydrogel platform and any future product candidates from the medical community and third-party payors; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third parties; |

| ● | our financial performance and our ability to repay our loans and debts; |

| ● | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses